Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy

Selective activation of pro-anti-IL-1β antibody enhances specificity for autoinflammatory disorder therapy

Abstract Canakinumab is a fully human monoclonal antibody that specifically neutralizes human interleukin (IL)-1β and has been approved by the US Food and Drug Administration for treating different types of autoinflammatory disorders such as cryopyrin-associated periodic syndrome, tumor necrosis fac...

Full description

Bibliographic Details
Main Authors: Wen-Wei Lin, Yun-Chi Lu, Bo-Cheng Huang, Chih-Hung Chuang, Yi-An Cheng, I.-Ju Chen, Hui-Ju Liu, Kai-Wen Ho, Tzu-Yi Liao, En-Shuo Liu, Ting-Yi Wu, Long-Sen Chang, Shih-Ting Hong, Tian-Lu Cheng
Format: Article
Language:English
Published: Nature Publishing Group 2021-07-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-021-94298-y

Internet

https://doi.org/10.1038/s41598-021-94298-y

Similar Items